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ABSTRACT
In 1999, the Blue Cross and Blue Shield Federal Employee Program (FEP) implemented a pi-
lot disease management program to manage congestive heart failure (CHF) among members.
The purpose of this project was to estimate the financial return on investment in the pilot
CHF program, prior to a full program rollout. A cohort of 457 participants from the state of
Maryland was matched to a cohort of 803 nonparticipants from a neighboring state where the
CHF program was not offered. Each cohort was followed for 12 months before the program
began and 12 months afterward. The outcome measures of primary interest were the differ-
ences over time in medical care expenditures paid by FEP and by all payers. Independent
variables included indicators of program participation, type of heart disease, comorbidity
measures, and demographics. From the perspective of the funding organization (FEP), the es-
timated return on investment for the pilot CHF disease management program was a savings
of $1.08 in medical expenditure for every dollar spent on the program. Adding savings to
other payers as well, the return on investment was a savings of $1.15 in medical expenditures
per dollar spent on the program. The amount of savings depended upon CHF risk levels. The
value of a pilot initiative and evaluation is that lessons for larger-scale efforts can be learned
prior to full-scale rollout. (Disease Management 2005;8:346-360)
INTRODUCTION
CHRONIC DISEASE is the leading cause of ill-ness, disability and death in the United
States, affecting nearly 100 million Americans.1
Heart failure alone affects nearly 4.7 million
Americans, with another 550,000 newly diag-
nosed cases each year.2 Although heart failure
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can afflict people of all ages, congestive heart
failure (CHF) mainly afflicts the elderly. CHF
prevalence increases with age and approaches
10% of Americans over 80 years old.3 Due to
an aging population and increasing survival
rates after diagnosis, the prevalence of heart
failure is expected to increase two- to threefold
in the coming decades.4
CHF directly and indirectly contributes to
about 285,000 deaths per year.2,5–8 It is the lead-
ing cause of hospitalization in the United
States.9 Despite treatment for CHF, readmis-
sions to hospitals after discharge remain all too
common, contributing to poor quality of life.
As such, the immense morbidity and mortality
associated with CHF increased medical costs
for that condition to over $20 billion per year
in the 1990s.5,10
Although the costs of CHF are high in terms
of direct medical costs and quality of life, prac-
tical interventions exist for controlling and 
preventing many chronic conditions, includ-
ing CHF. Reducing health risk factors is the
most important part of any intervention aimed
at reducing morbidity and mortality. Primar-
ily, CHF interventions encourage smoking ces-
sation; a low-fat, low-sodium diet; manage-
ment of high cholesterol; exercise; and the use
of effective medications such as angiotensin-
converting enzyme (ACE) inhibitors, digoxin,
and beta-blockers, all of which are currently
underused in the treatment of heart failure.11
This paper describes the economic (financial)
evaluation of a pilot CHF disease management
program funded by the federal Office of Per-
sonnel Management for members enrolled in
the BlueCross BlueShield Federal Employee
Program (FEP). A pilot program was under-
taken in one geographic area (Maryland) first,
prior to full-scale rollout of the program. The
value of a pilot approach is that it helped in-
form policy makers about likely return on in-
vestment prior to that rollout. Problems that
may be ameliorated were identified early, and
changes could be made to increase the likeli-
hood that the full-scale program would per-
form well and lead to a substantial return on
investment.
This study improves on previous evalua-
tions of CHF programs in several important
ways:
• To our knowledge, this study is the first eval-
uation of CHF patients at multiple risk lev-
els; it is not limited to those at high-risk, thus
having broader policy relevance.
• It estimates program impact vis-à-vis a com-
parison group, outside of a randomized ex-
periment, which was not feasible here; and
• It utilizes statistical methods to control for
regression to the mean and other secular
trends that might otherwise impact the ob-
served differences between the participant
and control groups.
Program description
In June 1998, the BlueCross BlueShield As-
sociation contracted with McKesson Inc. and
CorSolutions Inc. to administer a pilot program
for the management of CHF patients enrolled
as members in the FEP. McKesson managed 
a group of “at-risk” (ie, lower-risk) patients,
those who had fewer than two hospitalizations
for CHF in the previous year. CorSolutions pro-
vided its MULTIFIT Program exclusively to the
remaining “high-risk” patients. Eligible FEP
members in the state of Maryland were offered
an opportunity to enroll as voluntary partici-
pants in the CHF program.
The pilot CHF disease management program
was designed in accordance with clinical prac-
tice guidelines and administered to address
risks related to diet, exercise, medication man-
agement, and smoking behaviors. The program
used an individualized approach to member
assessment and provided education, counsel-
ing, and monitoring of patient progress.
The CHF program aimed to reduce health
risk factors among participants and was de-
signed to provide education, monitoring and
support for patients who chose to enroll. The
program focused heavily on the monitoring
and management of medications prescribed for
the patient by his or her physician. Consider-
able attention also was devoted to the man-
agement of the participant’s adherence to rec-
ommendations regarding appropriate self-care
practices. Such practices are designed to limit
complications arising from improper home
management of CHF. Similar programs have
been shown to reduce costs in other applica-
tions.12
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METHODS
Study design
A cohort of CHF program participants in
Maryland who were enrolled in the program
for at least 3 months was matched to a cohort
of non-participants from Virginia, where the
CHF program was not offered. Both groups
were otherwise covered by the same FEP health
plan. Participants within each cohort were as-
sessed for 12 months before the CHF program
began (February 1, 1999), and 12 months after-
ward. The average length of enrollment in the
CHF program was 11.3 months overall. En-
rollment did not vary much by risk; at-risk 
patients were enrolled for an average of 11.2
months, and high-risk participants were en-
rolled for an average of 11.7 months.
Study sample
Study subjects in Maryland were selected as
potential program participants based on their
claims data, which indicated diagnosis and
treatment codes for CHF. A comparison group
of non-participants who also had evidence of
CHF in their claims histories was drawn from
the FEP’s membership in northern Virginia,
where the program was not offered. Medical
records were not available for either group so
other evidence of CHF, such as low ejection
fraction, or New York Heart Association Class
III or IV measures, could not be used to find
CHF patients.
To qualify for inclusion in the study, indi-
viduals had to meet the following criteria:
• For participants, successful completion of the en-
rollment process by telephone. This entailed
making contact with the patient, confirming
CHF status, and securing the patient’s
agreement to participate.
• Availability of claims data for a 24-month pe-
riod. For participants, the period was defined
by the 12 months prior to enrollment in the pro-
gram and the 12 months following enrollment.
For a comparison group of non-partici-
pants, a proxy enrollment date was deter-
mined (using the enrollment date for the
participants to which they were matched),
and the same 24-month criterion was ap-
plied.
Enrollment and participation
A total of 3,843 plan members in Maryland
were referred to the program. Of these, 68%
(n  2,614) were able to be contacted by tele-
phone, after several attempts to reach them
were made at different times of the day. Of
those contacted, 1,429 or 55% enrolled in the
program. Of those enrolled, 53% (n  760)
completed intake assessments for the voluntary
program. Finally, a total of 457 CHF patients
completed at least three months of the program
(ie, 91 days) following enrollment, and met
other inclusion criteria noted below. The fi-
nancial performance of the FEP CHF program
was assessed on the basis of the experience of
this group of 457 program participants. A com-
parison group of non-participants also was se-
lected, as described below.
A number of inclusion restrictions were ap-
plied to CHF program participants before the
analyses were carried out. The goal was to al-
low more accurate estimation of the impact of
the CHF management program. On the basis
of advice from clinicians, claims for patients
with certain conditions were excluded from
analysis. The guiding principle was a desire to
eliminate the impact of high-cost illnesses
whose progression would not reasonably be 
affected by the CHF program. Thus, patients
with claims related to transplants, HIV/AIDS,
and end-stage renal disease were excluded
from the analysis due to very high condition-
related payments. (This criterion affected only
one patient in the sample, however.) Patients
with claims related to cancer were excluded,
but only if cancer-related payments exceeded
$5,000 per year. This cutoff was chosen after a
review of cancer claims revealed that only a
small number of individuals (n  9) had can-
cer-related spending above the $5,000 mark. Pa-
tients whose primary payer was Medicare at any
time during the 24-month study window (n 
66) were excluded, due to the likelihood that the
FEP would not capture all claims for those in-
dividuals. Finally, we excluded four patients
who died during the first year of the CHF pro-
gram. A total of 80 program participants were
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dropped from the study because they met one
or more of these exclusion criteria.
Selected claims were dropped for other in-
dividuals as well. All claims for poisoning by
substances other than food or drugs were ex-
cluded, as were trauma-related claims for eight
program participants whose traumas appeared
to be unrelated to CHF.
The same inclusion criteria and claims-han-
dling processes were used for nonparticipants.
(Additional information about the selection of
the comparison group is provided below.)
Since this study used a case-control design, ap-
plying the same inclusion and exclusion crite-
ria to both groups of patients helped to avoid
bias when return on investment (ROI) was es-
timated for the CHF program.
Choosing a comparison group
The Diagnostic Cost Grouper (DCG) risk-ad-
justment software package was used to cate-
gorize all program participants and potential
comparison group members into one or more
of 30 possible Aggregated Condition Cate-
gories (ACCs).13 ACC assignment was based
on patients’ ICD-9-CM diagnosis codes noted
during the 12-month pre-intervention period.
Treatment and comparison group members
with the same combination of the eight most
frequently found ACCs and gender were
matched. Using this method, 480 non-partici-
pants were matched to participants.
Several of the 457 program participants
could not be matched to any nonparticipant us-
ing the ACC and gender method. Thus, a sec-
ond matching process was used. We identified
the set of unique ICD-9-CM diagnoses assigned
to each CHF program participant during the
12-month pre-intervention period. The diagno-
sis codes were ranked according to frequency
and the five most common were chosen. We
then linked participants with nonparticipants
who had the same combination of ICD-9-CM
codes and gender. A total of 323 nonpartici-
pants were matched to program participants in
this manner. The final sample size of compar-
ison group members was 803.
After carrying out these procedures, there
were still 136 CHF program participants who
were not matched to anyone in the other group.
The 136 participants were left in the main anal-
ysis, however, even though they did not match
any nonparticipants, in order to maintain a
large enough sample for meaningful analysis.
Additional clinical, demographic, and other
variables were used in the multivariate analy-
ses described below to account for remaining
measurable differences between participants
and non-participants. Later, we conducted a
sensitivity analysis to see how results would
change if these 136 patients were dropped.
Analysis
Descriptive analyses. As described above, the
matching process used to link participants and
nonparticipants was not perfect, and some dif-
ferences between CHF program participants
and nonparticipants were expected. To assess
remaining differences between the two groups,
chi-square tests of independence were con-
ducted to compare the 457 treatment group
members to the 803 comparison group mem-
bers on the basis of demographics (age and
gender), type of heart disease observed in the
preprogram period, comorbidities, medica-
tions taken during that period, and the types
of healthcare services used before the CHF pro-
gram began.
The list of variables selected for comparison
was chosen after consultation with physicians
to determine which factors were likely to in-
fluence utilization trends for CHF patients. The
heart disease measures included indicators for
whether patients had rheumatic heart disease,
hypertensive heart disease, ischemic heart dis-
ease, or pulmonary heart disease.
To address comorbidity differences between
groups, we counted the number of unique ICD-
9-CM diagnosis codes observed during the
year prior to enrollment in the program. The
number and its square were included in our
statistical models. (Including the squared value
allowed us to control for any non-linear rela-
tionships between the number of illnesses and
expenditures.) We also included an indicator
for endocrine disorders because the DCG soft-
ware indicated these to be a problem whose
prevalence differed substantially between pro-
gram participants and nonparticipants.
The list of medications we considered in our
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analyses included those commonly prescribed
for CHF plus additional medications in the
same categories listed in the 1999 Drug Topics
Red Book.14 These included ACE inhibitors,
digoxin, diuretics, cardiac glycosides, calcium
channel blockers, hypotensives, vasodilators,
and other cardiac agents (eg, beta-blockers).
The list of healthcare services we considered
during the preprogram period included the use
of any nursing home care, any home care, any
CHF-related inpatient care, and any CHF-re-
lated outpatient office visits. Using these ser-
vices in the preprogram period was expected
to be associated with higher treatment costs.
Finally, descriptive analyses were used to
help interpret the ROI findings that were ob-
tained from the multivariate analyses de-
scribed below. For example, if the multivariate
analyses showed a beneficial change in med-
ical expenditures due to program participation,
descriptive studies could be advanced to help
find the source of those savings. To address this
issue, we also conducted t-tests to see whether
changes in payments for inpatient, outpatient,
and drug services may have occurred at dif-
ferent rates for program participants and non-
participants.
Multivariate analyses. The demographic, heart
disease, comorbidity, medication use, and ser-
vice use indicators mentioned above also were
used as independent variables in multiple re-
gression analyses to account for their impact on
healthcare expenditures before the impact of
the CHF program was estimated. We also con-
trolled for the impact of early disenrollment
from the program (ie, dropping out after three
months of participation, but before 12 months
of participation). Using the regression analyses
helped to adjust for any imperfections in the
matching process that were related to demo-
graphics, type of heart disease, comorbidities,
medication patterns, and previous service use.
Separate regression analyses were conducted
for high-risk and low-risk patients, using the
same control group for each. This was done be-
cause a Chow test showed that the demo-
graphics, heart disease, comorbidity, medica-
tion use, and service use variables had a
different impact on expenditures for each risk
group (p  0.0001). Thus, combining low- and
high-risk patients into the same analysis would
have distorted the program impact estimates,
leading to biased estimates of return on in-
vestment.
The dependent variable for each regression
analysis was defined as healthcare expendi-
tures during the 12-month period after the CHF
program began, minus expenditures during the
12-month period before it began. For the first
set of analyses, the dependent variable was de-
fined in terms of payments for these expendi-
tures that were made by the FEP. For a second
set of analyses, the dependent variable consid-
ered all expenditures, regardless of payer.
The major independent variable for each re-
gression analysis was an indicator denoting
whether patients participated in the at-risk 
or high-risk CHF programs administered by
McKesson and CorSolutions. This indicator
was included in addition to the demographic,
heart disease, service use, medication, and co-
morbidity measures noted above. The regres-
sion coefficients for the indicator of program
participation showed whether trends in ex-
penditures over time were higher or lower 
for program participants as compared to the
matched group of nonparticipants, after con-
trolling for the potentially confounding factors
mentioned above.
Calculating return on investment. All pay-
ments for medical care were cast in year 2001
dollars to adjust for inflation before the regres-
sion analyses were completed. An index based
upon the Gross Domestic Product Implicit
Price Deflator was used for the inflation ad-
justment, as suggested by Getzen.15
After the regression analyses were con-
ducted, we calculated the ROI and the net pres-
ent value (NPV) for the pilot CHF program.
The ROI figure is the estimated number of dol-
lars saved by the program, cast as a ratio per
dollar paid to the program vendors. The NPV
figure included the total program savings mi-
nus those vendor payments. If the CHF pro-
gram was cost beneficial (ie, if benefits ex-
ceeded costs), the NPV would be greater than
zero and the ROI ratio would be greater than
1.0.
Because all program participants and non-
participants were followed for only 1 year af-
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ter the CHF program began, the benefits and
costs of participation were not discounted to
adjust for the changing value of a dollar over
time. Only the inflation adjustment noted
above was made. The time horizon was short
enough to preclude the need to discount pro-
gram costs and benefits.
RESULTS
Sample characteristics
Table 1 compares baseline characteristics of
CHF program participants and comparison
group members across several dimensions. We
found differences in age group, primarily be-
cause the at-risk group varied from the com-
parison group in the age distribution. Some dif-
ferences in type of heart disease and pre-period
drug use were observed as well, with these
more likely to be due to differences between
high-risk participants versus comparison group
members. The high-risk participants also were
more likely to use home care or to have CHF-
related inpatient care in the preprogram pe-
riod.
Multivariate analyses
Multiple regression analyses were used to
control for demographic and other potential
confounding variables that could not easily be
controlled by the matching process. By con-
trolling for these potentially confounding fac-
tors, regression analyses provided a more ac-
curate estimate of program impact, accounting
for the differences found in Table 1 that re-
mained after matching.
Separate regressions were estimated for at-
risk and high-risk participants and the com-
parison group members. There were 339 at-risk
participants and 118 high-risk participants. 
Tables 2 and 3 report regression results, noting
the change over time in payments for these
groups relative to the comparison group mem-
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TABLE 1. SAMPLE CHARACTERISTICS DURING YEAR BEFORE CONGESTIVE HEART FAILURE (CHF) PROGRAM BEGAN
High-risk Chi-square Low-risk Chi-square Combined Chi-square
Control treatment test for treatment test for treatment test for
group group comparison group comparison group comparison
mean or mean or to control mean or to control mean or to control
percent percent group percent group percent group
Variable (n  803) (n  118) p-value (n  339) p-value (n  457) p-value
Age 30 1.50% 0.00% 0.22 0.00% 0.04 0.00% 0.01
Age 30–49 13.20% 9.32% 0.24 5.90% 0.01 6.78% 0.01
Age 50–69 62.39% 65.25% 0.55 82.60% 0.01 79.00% 0.01
Age 69 22.91% 23.73% 0.84 10.91% 0.01 14.22% 0.01
Female 45.85% 59.32% 0.01 48.08% 0.49 50.98% 0.08
Has rheumatic heart disease 7.35% 14.41% 0.01 7.08% 0.87 8.97% 0.31
Has hypertensive heart disease 56.66% 77.97% 0.01 69.32% 0.01 71.55% 0.01
Has ischemic heart disease 30.76% 75.42% 0.01 63.72% 0.01 66.74% 0.01
Has pulmonary heart disease 4.23% 11.86% 0.01 3.54% 0.59 5.69% 0.25
Has endocrine disorder 16.81% 22.88% 0.11 15.34% 0.54 17.29% 0.83
Used ACE inhibitor 25.53% 41.53% 0.01 31.27% 0.05 33.82% 0.01
Used digoxin 19.18% 31.36% 0.01 25.96% 0.01 27.35% 0.01
Used diuretics 28.77% 64.41% 0.01 43.66% 0.01 49.02% 0.01
Used cardiac glycosides, calcium 13.70% 23.73% 0.01 13.27% 0.85 15.97% 0.27
channel blockers, hypotensives,
vasodilators, and other cardiac
agents
Used nursing home 4.98% 9.32% 0.05 0.88% 0.01 3.06% 0.11
Used home care 20.05% 40.68% 0.01 15.63% 0.08 22.10% 0.39
Had CHF-related inpatient stay 25.90% 57.63% 0.01 23.01% 0.30 31.95% 0.02
Had CHF-related outpatient visit 73.85% 89.83% 0.01 91.74% 0.01 91.25% 0.01
No. of diagnosis codes 16.91 21.40 0.01 15.07 0.01 16.71 0.74
1998–2000 FEP Data.
bers. Table 2 shows that a typical at-risk par-
ticipant enrolled in the CHF program saved the
FEP about $999.34 per year, but this result was
not statistically significant (p  0.44). Once all
other payers were considered, savings in-
creased slightly to $1,112.16 per patient per
year, but the results still were not statistically
significant (p  0.43).
Table 3 shows that a typical high-risk par-
ticipant enrolled in the CHF program saved the
FEP health plan $4,581.22 (p  0.04). Results for
all payers suggest a savings of $4,754 per pa-
tient (p  0.05).
Regardless of payer, a number of other vari-
ables were significant in the expenditure re-
gression models. Trends in cost over time
were significantly lower for at-risk patients
who had diagnoses for rheumatic, ischemic,
or pulmonary heart disease in the pre periods
or endocrine disorders during that period,
compared to others without these diseases
(Table 2).
Cost increases also were lower for high-risk
patients who had rheumatic, ischemic, and
pulmonary heart disease in the pre period as
compared to patients without these disorders
(Table 3).
Finally, we found greater savings associated
with patients who had received more intensive
care prior to enrollment, as evidenced by
claims for nursing homes (in three of the four
regression models), home care, or a CHF-re-
lated hospitalization. The use of major heart
medications (ACE inhibitors, dioxins, or di-
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TABLE 2. REGRESSION ANALYSIS OF DIFFERENCE (POST-PRE) IN TOTAL PAYMENTS
FOR AT-RISK PARTICIPANTS AND COMPARISON GROUP MEMBERS
All payers FEP only
Independent variable Coefficient SE p-value Coefficient SE p-value
Treatment programs
AHG program participant 1112.16 1408.50 0.43 999.34 1294.89 0.44
Early disenrollment: number of monthsa 1368.67 462.76 0.01 1428.18 425.43 0.01
Demographics
Age 30–49 1085.65 1888.02 0.57 1132.67 1735.73 0.51
Age 70 or more 1189.11 1541.55 0.44 640.64 1417.21 0.65
Female 1784.05 1198.80 0.14 1798.09 1102.10 0.10
Pre-program diagnoses
Rheumatic heart disease 3991.17 2239.12 0.07 3550.76 2058.51 0.08
Hypertensive heart disease 1101.48 1320.74 0.40 831.41 1214.21 0.49
Ischemic heart disease 3731.95 1336.71 0.01 3697.01 1228.89 0.01
Pulmonary heart disease 6667.53 3021.65 0.03 6113.80 2777.92 0.03
Endocrine disorders 4011.96 1592.93 0.01 3684.70 1464.44 0.01
Number of unique 3-digit ICD-9 codes 167.54 166.01 0.31 117.12 152.62 0.44
Square of number of unique ICD-9 codes 20.60 3.35 0.01 19.84 3.08 0.01
Pre-program medication use
Any ACE inhibitor 491.76 1343.93 0.71 479.50 1235.53 0.70
Any digoxin 2516.86 1536.43 0.10 2137.62 1412.50 0.13
Any diuretic 823.25 1328.84 0.54 950.28 1221.65 0.44
Pre-program CHF-related service use
Any nursing home care 7115.09 3179.57 0.03 4453.13 2923.11 0.13
Any home care 9405.46 1604.54 0.01 8076.48 1475.12 0.01
Any CHF-related inpatient admission 1652.62 150.34 0.01 1480.56 138.21 0.01
Any CHF-related outpatient office visit 3643.31 1633.07 0.03 3232.00 1501.35 0.03
Intercept 5195.31 2050.53 0.01 5058.27 1885.14 0.01
R squared 0.38 0.38
aEqual to (12  [no. of months enrolled]); range 0–9.
1998–2000 FEP Data.
uretics) in the pre period was not associated
with differences in payments over time for ei-
ther patient group.
Return on investment estimates
The regression coefficients from Tables 2 and
3 were multiplied by the associated number of
at-risk and high-risk program participant-years
to estimate the total dollars saved by the CHF
program. These savings were then compared
to total program expenditures to estimate ROI
and NPV. The results are reported in Table 4.
Overall, Table 4 shows that the CHF program
saved money. The FEP invested about $1,706
for each of the 457 patients enrolled in the pro-
gram and saved $1,841 per enrollee. In total,
the FEP saved about $61,728 on the pilot CHF
program, resulting in an ROI of $1.08 in med-
ical care expenditure savings for every dollar
invested in the program. Accounting for all 
payments regardless of payer (ie, including co-
payments, deductibles, and coordination-of-
benefit payments from other insurers, thereby
invoking a broader perspective), the ROI esti-
mate increased to $1.15 in savings per dollar
spent on the program.
We also found that the ROI varied according
to patient risk level (Table 4). Payments for each
of the 118 patients enrolled in the high-risk pro-
gram were $4,697 whereas savings were $4,581,
a lower amount. Thus, this program led to a
modest loss of about $27,746 for the FEP. The
ROI was $0.95, a loss of about $0.05 per dollar
spent on the program. The loss was about
$7,834 when all payers were considered, re-
CHF DISEASE MANAGEMENT 353
TABLE 3. REGRESSION ANALYSIS OF DIFFERENCE (POST-PRE) IN TOTAL PAYMENTS
FOR HIGH-RISK PARTICIPANTS AND COMPARISON GROUP MEMBERS
All payers FEP only
Independent variable Coefficient SE p-value Coefficient SE p-value
Treatment programs
CorSolutions program participant 4754.50 2426.22 0.05 4581.22 2250.42 0.04
Early disenrollment: number of monthsa 3047.34 911.56 0.01 2849.84 845.51 0.01
Demographics
Age 30–49 1729.90 2212.04 0.43 1677.81 2051.76 0.41
Age 70 or more 1707.40 1803.24 0.34 1355.29 1672.58 0.42
Female 2030.50 1503.49 0.18 2108.05 1394.54 0.13
Pre-program diagnoses
Rheumatic heart disease 8934.26 2678.35 0.00 8053.02 2484.28
Hypertensive heart disease 1778.14 1668.01 0.29 1732.76 1547.15 0.26
Ischemic heart disease 4806.97 1732.55 0.01 4446.46 1607.01
Pulmonary heart disease 7109.98 3397.01 0.04 6361.15 3150.87 0.04
Endocrine disorders 2447.50 1950.42 0.21 2118.52 1809.10 0.24
Number of unique 3-digit ICD-9 codes 344.74 201.04 0.09 288.44 186.48 0.12
Square of number of unique ICD-9 codes 15.91 3.85 0.01 15.40 3.57 0.01
Pre-program medication use
Any ACE inhibitor 876.60 1710.61 0.61 697.86 1586.66 0.66
Any digoxin 2713.74 1946.12 0.16 2347.75 1805.11 0.19
Any diuretic 2175.49 1711.53 0.20 2151.32 1587.52 0.18
Pre-program CHF-related service use
Any nursing home care 7869.81 3303.19 0.02 6966.49 3063.84 0.02
Any home care 8994.17 1891.39 0.01 7907.92 1754.34 0.01
Any CHF-related inpatient admission 1712.38 182.59 0.01 1552.01 169.36 0.01
Any CHF-related outpatient office visit 1651.17 1960.22 0.40 1404.81 1818.18 0.44
Intercept 4160.34 2490.69 0.10 4188.23 2310.21 0.07
R squared 0.39 0.38
aEqual to (12  [no. of months enrolled]); range 0–9.
1998–2000 FEP Data.
sulting in an ROI estimate of $0.99 (ie, a loss of
a penny per dollar spent on the program).
For the 339 at-risk patients, program spend-
ing was $665 and program savings were $999–
$1,112 per patient, thus producing an ROI of be-
tween $1.40 and $1.55 per dollar spent on the
program.
Changes in service use and medications
The regression analyses presented in Tables
2 and 3 and the NPV and ROI figures pre-
sented in Table 4 show that the CHF program
seemed to be cost beneficial for at-risk pa-
tients, and was roughly a breakeven endeavor
for high-risk patients. However, these tables
do not explain why that may be the case. Data
presented in Table 5 provide some clues as to
the possible sources of program savings.
Table 5 shows differences in inpatient, out-
patient, and pharmaceutical payments over
time for the year before and the year after the
CHF program began, comparing program
participants to nonparticipants. These differ-
ences were not adjusted via regression anal-
ysis, and are therefore more speculative, but
still may provide a rough perspective on why
the ROI values noted above were obtained.
The top three rows in the table show that av-
erage medical (inpatient and outpatient) pay-
ments decreased over time for program par-
ticipants, while these payments increased
over time for nonparticipants. These unad-
justed expenditure trends were significantly
different for participants vs. nonparticipants
(t-test p-values  0.05).
The next several rows of the table show un-
adjusted changes over time in payments for
various types of pharmaceuticals. Only a few
of these were significant and, in dollar terms,
they tended to show lower pharmaceutical ex-
penditures for nonparticipants. For example,
total CHF-related drug payments increased by
about $208 on average for program partici-
pants, but increased only about $155 on aver-
age for nonparticipants. This is due primarily
to a larger increase in payments for ACE in-
hibitors for program participants. This may re-
flect improved quality of care, however, be-
cause ACE inhibitors are recommended for all
CHF patients. There was also a slightly higher
increase in drug payments due to the use of va-
sodilators among program participants (ie, ex-
penditures for vasodilators increased by $29.56
for participants on average, but only by $19.83
on average for nonparticipants).
Taken together, the results noted in Table 5
suggest that declines in inpatient and outpa-
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TABLE 4. NET PRESENT VALUE AND RETURN ON INVESTMENT IN CONGESTIVE
HEART FAILURE (CHF) PROGRAM, IN YEAR 2001 DOLLARS
Payments by FEP Payments by all payers
Net Return Net Return
present on $1.00 present on $1.00
value investment value investment
A. All participants (n  457)
Average savings in all payments (pre  post) $841,499.92 $896,979.75
Total program expenses $779,771.88 $779,771.88
Total program benefit (net present value) $61,728.04 $1.08 $117,207.87 $1.15
B. High-risk participants (n  118)
Average savings in all payments (pre  post) $526,458.73 $546,371.18
Total program expenses $554,205.10 $554,205.10
Total program benefit (net present value) $27,746.37 $0.95 $7,833.92 $0.99
C. Low-risk participants (n  339)
Average savings in all payments (pre  post) $315,041.19 $350,608.57
Total program expenses $225,566.78 $225,566.78
Total program benefit (net present value) $89,474.41 $1.40 $125,041.79 $1.55
Savings estimates are based upon multivariate analyses, adjusted for length of program participation.
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tient expenditures that may be due to program
participation were not offset by increased drug
use; these changes may have led to the positive
ROI and NPV figures reported above.
Sensitivity analyses
We conducted sensitivity analyses to learn
how the program impact estimates would
change if we dropped the 136 CHF patients
who could not be matched to comparison
group members. Excluding these 136 program
participants had a mixed impact on the results.
After dropping 87 unmatched participants
who were in the at-risk group, the estimated
savings to the FEP increased to $1,011.29 per
person per year (p  0.49); this compares to the
estimated savings of $999.34 (p  0.44) that was
noted in the main analysis that did not exclude
these 87 patients. The roughly $11 difference in
these two impact estimates would have had a
very minor impact on ROI for the at-risk group.
In contrast, dropping these 87 unmatched par-
ticipants from the analysis of expenditures by
all payers (not just FEP) led to a substantially
greater savings estimate of $1,235.96 per per-
son per year, compared to the $1,112 figure ob-
tained prior to dropping these participants.
However, the results still were not statistically
significant (p  0.44).
Dropping the high-risk participants who
could not be matched to any comparison group
members had a large impact on the results as
well. After dropping those 49 patients, the es-
timated savings to the FEP decreased from
$4,581.22 (p  0.04) to $4,191.73 per person per
year (p  0.15). This reduced the ROI for the
high-risk group by roughly 8.5%. When pay-
ments by all payers were considered, the new
savings estimate was $4,509.86 per person per
year (p  0.15), compared to the $4,754.50 esti-
mate obtained prior to dropping the un-
matched participants. Thus, the ROI estimate
dropped by about 5.1%.
In summary, dropping the unmatched high-
risk participants reduced savings and led to
statistically insignificant findings. The lack of
significance should not be surprising, however,
because only 69 high-risk participants were left
after dropping the 49 who could not be
matched to comparison group members.
DISCUSSION
Medical claims data were analyzed to find
trends in medical expenditures for CHF pa-
tients who participated in a pilot disease man-
agement program offered to federal employ-
ees. Most program participants were matched
to a comparison group of patients in a neigh-
boring state who had identical health insurance
plan features, but who were not offered en-
rollment in the CHF program. Regression
analyses were used to control for the remain-
ing measurable differences between program
participants and nonparticipants.
Overall, we found the CHF disease manage-
ment program to be cost beneficial, saving the
health plan about $1.08 in medical expendi-
tures for every dollar invested in the program.
Adding benefits to patients (in the form of
fewer copayments or deductibles resulting
from lower service use) and other payers, the
program saved $1.15 in medical expenditures
for every dollar spent on it.
ROI estimates varied according to level of
risk, however, and others may want to take
note and design their evaluations accordingly.
In our case, ROI estimates were higher for at-
risk (ie, lower risk) patients. Thus, a pilot ROI
analysis may suggest that program sponsors or
vendors pay more attention to refinements that
can lead to higher ROI for particular subsets of
patients as programs are expanded beyond the
pilot stage.
The cost savings reported here are similar to
estimates derived from studies of other CHF
disease management programs.16 A review of
16 studies found that CHF programs often re-
sulted in decreased hospitalization.17 While
most disease management programs for CHF
seem to work by reducing hospital length of
stay or readmission rates,12,18 the impact is not
always statistically significant19 and the success
of these programs may be a function of the
types of patients enrolled and the severity of
their illnesses.9,20 In our analysis, we stratified
program participants by risk status and con-
trolled for differences in comorbidities. The 
impact of disease management on medical ex-
penditures was greater and statistically signif-
icant among the high-risk patients we studied,
but program costs were higher for them too.
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Because of the higher program costs, the NPV
and ROI figures were more favorable for the
at-risk (ie, lower risk) patients.
Overall, we found a positive ROI for the CHF
disease management program. Cost savings
were realized even though spending for pre-
scription drugs appeared to be higher for pro-
gram participants than for nonparticipants.
Thus, a positive ROI may have been due, in
part, to improvements in medication use (eg,
higher increases in the use of ACE inhibitors
and digoxin, which often are recommended for
CHF patients21) and lower inpatient and out-
patient service use for participants as com-
pared to nonparticipants.
Limitations
The analyses we conducted were limited by
several factors. These included (1) a small sam-
ple size, (2) the imperfect matching process, (3)
the voluntary nature of program participation,
(4) the inability to randomize patients to treat-
ment or control group status, (5) a relatively
short outcome period of interest (1 year), and (6)
a primary focus on monetary outcomes that ex-
cluded description of the program’s impact on
quality of life. Each of these is addressed below.
First, the pilot nature of our study resulted
in a small sample of program participants (al-
though the 457 participants included here are
still greater in number than those reported in
some other studies20,22,23). Apparently this was
more problematic for low-risk beneficiaries,
causing the impact estimate for this group to be
statistically insignificant (ie, p  0.05; Table 2).
Expanding upon this notion for a moment, it
is worth some discussion of why the statistically
insignificant impact estimate for the low-risk
group was used in the ROI and NPV formulas.
If the impact estimate cannot be differentiated
from zero dollars statistically, does this mean
that zero is a better estimate of program im-
pact? The answer to this question is “no.” The
ordinary least squares (OLS) regression proce-
dure used for the analysis provides what is
commonly known as the “best linear unbiased
estimate” of program impact. This means that,
in the class of linear models, there is no other
estimate which is more accurate and more ef-
ficient than the one produced by OLS regres-
sion.24 The fact that the estimate has a confi-
dence interval that includes zero dollars should
lead readers to note its inherent variability with
a sample this size, but not its accuracy. Zero is
neither a more accurate nor a more likely an-
swer to the question of the impact of the CHF
program for low-risk patients, so zero dollars
should not be used in the ROI and NPV for-
mulas.
The second limitation of the evaluation re-
lates to the imperfect matching process that
was used. We noted that 136 of the CHF pro-
gram participants could not be matched on the
basis of ACC category or diagnosis. Other
matching algorithms, such as propensity score
matching, could have been tried. However, no
matching process can ever be perfect, and even
propensity score matches (which are designed
to match on the basis of several variables at
once) often require supplemental regression
analyses to control for variables that are still
significantly different between treatment and
comparison group members after matching is
completed.25
We addressed the imperfect matching by us-
ing regression analyses to control for several
demographic and case mix-related variables
that were significantly different between par-
ticipants and nonparticipants. We also con-
ducted sensitivity analyses to see how results
for the primary payer (FEP) would change af-
ter dropping the 136 CHF program participants
who could not be matched to nonparticipants.
Dropping these participants tended to raise the
ROI estimates for at-risk patients and reduce
the ROI estimates for high-risk patients. The re-
ductions among the high-risk patients were as-
sociated with the loss of 41% of the high-risk
participants, though, casting doubt on the util-
ity of dropping these patients.
The third limitation of the evaluation deals
with the voluntary nature of the CHF disease
management program. Because it was volun-
tary, a substantial number of patients refused
to enroll or dropped out within 90 days of en-
rollment. Although the results might have been
different if enrollment had been higher, two
factors help lessen this concern. First, decisions
regarding inclusion and exclusion criteria were
made before analyses were begun. Second, the
research organization performing the evalua-
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tion was paid by the health plan and not the
program vendors, in order to ensure objectiv-
ity. We therefore expect internal validity of this
study was high, noting that a matched com-
parison group was used and other adjustments
were carried out in the multivariate analyses to
limit threats to internal validity.
Considered together, the first two limitations
of our study (ie, the small sample size and vol-
untary nature of the program) might have re-
sulted in a sample that was highly motivated
to change their behavior. Without a direct mea-
sure of motivation for those who participated
and those who did not, it is not possible to sep-
arate the impact of motivational factors from
the impact of program participation. However,
it seems reasonable to expect that the associ-
ated reduction in expenditures may not have
taken place as quickly without a CHF program
to serve as a stimulus for that change.
Another limitation of our study was the in-
ability to test the CHF program as part of a ran-
domized controlled trial. As a result, there may
be unmeasurable differences between program
participants and nonparticipants that influ-
enced our findings. We attempted to avoid bias
by selecting a comparison group from a neigh-
boring state subject to the same insurance pro-
gram and the same inclusion criteria, and by
using regression analyses to control for mea-
surable differences between program partici-
pants and nonparticipants. However, some 
unmeasured differences may still remain and
these differences may have influenced findings
to an unknown degree. Selection bias due to
unmeasurable differences in treatment and
control group members would exist regardless
of which matching strategy is chosen in non-
randomized studies.
Next, the focus of this study was on ROI af-
ter only 1 year of program implementation. In
many disease management programs, it may
take more than 1 year to realize gains from
changes in behavior that are induced by the
program. In addition, program providers may
learn to be more efficient as time goes on, and
may reap benefits in later years that cannot be
experienced in the first program year. Thus, the
ROI for subsequent years may be higher than
the ROI estimated for the first year.
Finally, this study focused primarily on 
financial outcomes. Even though economic
studies can yield rational decisions about the
usefulness of CHF disease management pro-
grams,26 they are not complete. Nonmonetary
outcomes also should be considered before a
complete understanding of the impact of the
program is obtained.
Lessons from the CHF application
Health plans may wish to pilot test their pro-
grams to find out what the likely impact of their
programs may be before rolling out to a larger
audience, as the sponsoring health plan did
here. Lessons from the pilot test can be gained
via empirical evaluation. Some lessons gained
from the CHF application described here are as
follows:
1. Pilot tests typically involve small samples.
These small samples may have substantial
variability in medical expenditures. The ap-
propriate sample size for the pilot can be in-
formed by conducting power analyses to es-
timate the size of the pilot needed to be able
to detect a significant program effect.
2. It can be cumbersome and difficult to match
treatment and comparison group members.
More systematic methods, such as the use of
propensity score techniques, are gaining
popularity and should be considered.
3. Regardless of the matching strategy, tests for
differences between treatment and compar-
ison group members should be conducted
and statistical analyses should be used to ad-
just for any remaining differences.
4. Despite the intricacies involved in adjusting
for differences, a comparison group should
be used. Otherwise it will not be possible to
infer whether observed changes are really
due to program participation.
5. The results of the ROI estimation process
may vary by level of patient risk. Thus, pol-
icy implications also may vary for different
patient subgroups.
6. No vendor is perfect, no program is perfect,
no sponsor is perfect, and no evaluation is
perfect. Mistakes can be made inadvertently
at many levels. Thus “bad” or unexpected
results should be viewed as opportunities
for discussions about how to better organize
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programs, how to run them more efficiently,
and how to better work with patients and
providers. A key benefit of conducting a pi-
lot study is that these discussions can occur
prior to full-scale rollout, thereby benefiting
patients and health plans tremendously,
once the larger rollout of the program is im-
plemented.
CONCLUSIONS
The pilot CHF disease management program
offered to FEP enrollees seemed to be cost ben-
eficial overall during its initial year of opera-
tion. For high-risk patients, it was roughly a 
financial breakeven program. For at-risk pa-
tients, the return was higher but less certain.
Savings from the program probably resulted
from decreases in inpatient and outpatient ex-
penditures that were not offset by an increase
in pharmaceutical spending. These results were
obtained for a sample of CHF patients that in-
cluded low-risk as well as high-risk patients,
potentially broadening the application and
benefits of a CHF disease management pro-
gram to a much larger pool of patients than pre-
viously thought possible.
It has been noted that many CHF disease
management program evaluations have been
conducted with little rigor and that their re-
ported results often rely on before-and-after
study designs that exclude comparison or con-
trol groups.27,28 This may make their conclu-
sions suspect. In our case, a comparison group
was included. Randomization was not feasible,
so we used matching techniques and multiple
regression analyses to adjust for differences be-
tween program participants and comparison
group members. The matching methods we
used were not perfect, and several of the treat-
ment group members found no corresponding
match in the control group based upon gender
and comorbidities. We relied on multiple re-
gression analyses to control for remaining dif-
ferences, but it is still possible that unobserved
differences between the two groups influenced
our results. Other health plans are likely to
have the same problem when their evaluations
are conducted, because matching involves art
as well as science. Nevertheless, researchers are
advised to look for ways to balance the samples
of treatment and comparison group members
when analyses are conducted. Matching and re-
gression-based methods may limit regression to
the mean and other threats to validity. Thus,
they generally are preferred to the absence of a
comparison group or to less rigorous attempts
to control for differences between program par-
ticipants and nonparticipants.28
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